-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
AN2 Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2021 to 2024.
- AN2 Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$8.6M, a 54.3% increase year-over-year.
- AN2 Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$56.8M, a 18.4% increase year-over-year.
- AN2 Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$56.8M, a 18.4% increase from 2023.
- AN2 Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$69.6M, a 64.8% decline from 2022.
- AN2 Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$42.3M, a 95.9% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)